Thermo Fisher (TMO) stock slips as the company issues underwhelming guidance after beating Street forecasts with its Q4 2025 ...

Thermo Fisher Scientific Inc.'s TMO fourth-quarter 2025 adjusted earnings per share (EPS) of $6.57 beat the Zacks Consensus ...

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.57 per share, beating the Zacks Consensus Estimate of ...

Thermo Fisher Scientific Inc (TMO) reports robust financial performance with significant revenue growth and strategic ...

Investing.com - Thermo Fisher Scientific (NYSE: TMO) reported fourth quarter EPS of $6.57, $0.12 better than the analyst estimate of $6.45. Revenue for the quarter came in at $12.21B versus the ...

Thermo Fisher Scientific Inc.’s TMO recent slew of strategic acquisitions reflects its ongoing commitment to sustainable long-term growth. End markets play an important role as well, bolstering Thermo ...

TMO ramps up acquisitions and product launches to drive growth, but heavy debt and currency headwinds raise questions for long-term holders.

Thermo Fisher is well-positioned for continued revenue growth driven by easing pharma uncertainty, reshoring, and recovering clinical research trends. Margins should expand through operating leverage, ...

Thermo Fisher Scientific has received a total of 8 ratings from analysts, with the consensus rating as Buy. With an average ...

Thermo Fisher Scientific Inc. TMO focuses on expanding through the acquisition of technologies and businesses that augment its existing products and services. The company continues to enhance its ...